Anti-Inflammatory and Antifibrotic Potential of Longidaze in Bleomycin-Induced Pulmonary Fibrosis

• Published in: Life (Basel, Switzerland) Switzerland), 2023-09, Vol.13 (9), p.1932
• Main Authors: Pakhomova, Angelina, Pershina, Olga, Bochkov, Pavel, Ermakova, Natalia, Pan, Edgar, Sandrikina, Lubov, Dagil, Yulia, Kogai, Lena, Grimm, Wolf-Dieter, Zhukova, Mariia, Avdeev, Sergey
• Format: Article
• Language: English
• Subjects: Animal experimentation; Anti-inflammatory agents; Anti-inflammatory drugs; Biopharmaceutics; Bleomycin; Collagen; Collagen (type I); Complications and side effects; Connective tissue; Connective tissues; COVID-19; Disease; Drug dosages; Drug therapy; Enzyme-linked immunosorbent assay; Enzymes; Ethylenediaminetetraacetic acid; Extracellular matrix; Fibrosis; Growth factors; Hematology; Histology; Hyaluronic acid; Hydroxyproline; idiopathic pulmonary fibrosis; Inflammation; Inflammatory response; interstitial lung disease; Laboratory animals; Longidaze; Lung diseases; Lungs; Medical prognosis; Mice; Molecular weight; Pathogenesis; Pulmonary fibrosis; Regenerative medicine; Testing; Tissues; Transforming growth factor-b1; Transforming growth factors; Tumor necrosis factor-TNF; Tumor necrosis factor-α
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life13091932

Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung disease, characterized by progressive parenchymal fibrosis and respiratory failure. In a model of bleomycin-induced pulmonary fibrosis, the antifibrotic and anti-inflammatory activity of Longidaze (Bovhyaluronidase Azoxymer), which contains a conjugate of the hyaluronidase enzyme with a high molecular weight synthetic carrier azoxymer bromide, was investigated. Experiments were conducted in male C57BL/6 mice. Longidaze was administered at different doses by intranasal and intramuscular routes. Histology, hematology, and enzyme-linked immunosorbent assay were used in the study. The use of Longidaze reduced pulmonary fibrosis, as evidenced by an improvement in histopathologic damage to the lungs, a decrease in the area of connective tissue, and the levels of profibrotic factors (TGF-β1, hydroxyproline, collagen I) in lung tissue. In addition, Longidaze inhibited the inflammatory response in pulmonary fibrosis, and decreased the levels of IL-6, TNF-α, and hyaluronic acid in lung tissue and the recruitment of inflammatory cells into lung tissue. The highest therapeutic efficacy was observed with the use of Longidaze at doses of 120 and 1200 U/kg intramuscularly, which was superior to that of the reference drug pirfenidone axunio. The data presented in this study suggest that Longidaze is a new and promising drug for the treatment of IPF that warrants further investigation in patients with fibrotic interstitial lung disease.